Xeris Pharmaceuticals | XERS - Cost Of Sales



Xeris Pharmaceuticals reported $11.9M in Cost of Sales for its fiscal quarter ending in June of 2025.


Cost Of Sales Change Date
Adcock Ingram Holdings ZAR 3.18B 115.21M Dec/2024
Celltrion KRW 399.04B 120.81B Mar/2025
Cspc Pharmaceutical CNY 2.31B 299.94M Mar/2025
Divis Laboratories Ltd 10.68B 870M Jun/2025
Eli Lilly USD 2.45B 223.6M Jun/2025
Kangmei Pharma CNY 1.03B 35.75M Jun/2025
Knight Therapeutics CAD 47.25M 990K Sep/2024
Laboratorios Farma EUR 54.41M 97.64M Jun/2025
Malin Corporation EUR 15.4M 0 Dec/2020
Medical Developments International AUD 5.27M 2.92M Dec/2024
Organigram Holdings CAD 44.65M 2.96M Jun/2025
Pacira USD 55.19M 20.88M Jun/2025
Perrigo USD 693.4M 41.8M Jun/2025
Pharma Mar EUR 2.78M 620K Jun/2025
Qiagen NV USD 199.25M 24.48M Jun/2025
Sartorius EUR 468.1M 16.1M Jun/2025
Sino Biopharmaceutical CNY 2.49B 353.34M Dec/2024
Supernus Pharmaceuticals USD 37.65M 21.88M Jun/2025
Tilray USD 149.73M 9.39M Nov/2024
Zz Pientze Pharmaceu 1.94B 214.76M Jun/2025